Literature DB >> 1992137

Inhibitors of cholesterol biosynthesis. 3. Tetrahydro-4-hydroxy-6-[2-(1H-pyrrol-1-yl)ethyl]-2H-pyran-2-one inhibitors of HMG-CoA reductase. 2. Effects of introducing substituents at positions three and four of the pyrrole nucleus.

B D Roth1, C J Blankley, A W Chucholowski, E Ferguson, M L Hoefle, D F Ortwine, R S Newton, C S Sekerke, D R Sliskovic, C D Stratton.   

Abstract

A series of trans-tetrahydro-4-hydroxy-6-[2-(2,3,4,5-substituted-1H-pyrrol-1-yl) ethyl]-2H-pyran-2-ones and their dihydroxy acids were prepared and tested for their ability to inhibit the enzyme HMG-CoA reductase in vitro. Inhibitory potency was found to increase substantially when substituents were introduced into positions three and four of the pyrrole ring. A systematic exploration of structure-activity relationships at these two positions led to the identification of a compound ((+)-33,(+)-(4R)-trans-2-(4-fluororphenyl)-5-(1-methylethyl)-N,3- diphenyl-1- [(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1H-pyrrole-4- carboxamide) with five times the inhibitory potency of the fungal metabolite compactin.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1992137     DOI: 10.1021/jm00105a056

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  16 in total

Review 1.  Carbene catalysts.

Authors:  Jennifer L Moore; Tomislav Rovis
Journal:  Top Curr Chem       Date:  2010

2.  The interconversion kinetics, equilibrium, and solubilities of the lactone and hydroxyacid forms of the HMG-CoA reductase inhibitor, CI-981.

Authors:  A S Kearney; L F Crawford; S C Mehta; G W Radebaugh
Journal:  Pharm Res       Date:  1993-10       Impact factor: 4.200

3.  A potent and highly efficacious Bcl-2/Bcl-xL inhibitor.

Authors:  Angelo Aguilar; Haibin Zhou; Jianfang Chen; Liu Liu; Longchuan Bai; Donna McEachern; Chao-Yie Yang; Jennifer Meagher; Jeanne Stuckey; Shaomeng Wang
Journal:  J Med Chem       Date:  2013-03-22       Impact factor: 7.446

Review 4.  A continuum of progress: applications of N-hetereocyclic carbene catalysis in total synthesis.

Authors:  Javier Izquierdo; Gerri E Hutson; Daniel T Cohen; Karl A Scheidt
Journal:  Angew Chem Int Ed Engl       Date:  2012-10-16       Impact factor: 15.336

5.  Structure-based design of potent Bcl-2/Bcl-xL inhibitors with strong in vivo antitumor activity.

Authors:  Haibin Zhou; Angelo Aguilar; Jianfang Chen; Longchuan Bai; Liu Liu; Jennifer L Meagher; Chao-Yie Yang; Donna McEachern; Xin Cong; Jeanne A Stuckey; Shaomeng Wang
Journal:  J Med Chem       Date:  2012-07-02       Impact factor: 7.446

6.  Lipid-lowering effects of ethyl 2-phenacyl-3-aryl-1H-pyrrole- 4-carboxylates in rodents.

Authors:  Justin M Holub; Kathy O'Toole-Colin; Adam Getzel; Anthony Argenti; Michael A Evans; Daniel C Smith; Gerard A Dalglish; Shahzad Rifat; Donna L Wilson; Brett M Taylor; Ulander Miott; Josephine Glersaye; Kam Suet Lam; Bryan J McCranor; Joshua D Berkowitz; Robert B Miller; John R Lukens; Keith Krumpe; John T Gupton; Bruce S Burnham
Journal:  Molecules       Date:  2004-02-28       Impact factor: 4.411

7.  Functional-group-tolerant, nickel-catalyzed cross-coupling reaction for enantioselective construction of tertiary methyl-bearing stereocenters.

Authors:  Hanna M Wisniewska; Elizabeth C Swift; Elizabeth R Jarvo
Journal:  J Am Chem Soc       Date:  2013-06-10       Impact factor: 15.419

8.  rac-2-[2-(4-Fluoro-phen-yl)-2-oxo-1-phenyl-eth-yl]-4-methyl-3-oxo-N-phenyl-penta-namide.

Authors:  Feng-Yan Zhou; Jian-Ying Huang
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2010-11-13

9.  An overview of the key routes to the best selling 5-membered ring heterocyclic pharmaceuticals.

Authors:  Marcus Baumann; Ian R Baxendale; Steven V Ley; Nikzad Nikbin
Journal:  Beilstein J Org Chem       Date:  2011-04-18       Impact factor: 2.883

10.  An improved kilogram-scale preparation of atorvastatin calcium.

Authors:  Yuri V Novozhilov; Mikhail V Dorogov; Maria V Blumina; Alexey V Smirnov; Mikhail Krasavin
Journal:  Chem Cent J       Date:  2015-02-13       Impact factor: 4.215

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.